Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Ettrich · SciRah

Researcher profile · Semantic Scholar

T. Ettrich

Share profile

T. Ettrich — researcher profile on SciRah

h-index: 23
Works: 122
Citations: 2,017

Most-cited papers

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
O. Türeci, U. Şahin, H. Schulze-Bergkamen, Z. Zvirbule +16 more
2019Annals of Oncology239 citations Open access
Semantic Scholar
FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).
D. Modest, U. Martens, J. Riera-Knorrenschild, J. Greeve +15 more
2019Journal of Clinical Oncology177 citations
Semantic Scholar
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group.
T. Seufferlein, W. Uhl, M. Kornmann, H. Algül +31 more
2022Annals of Oncology163 citations Open access
Semantic Scholar
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
V. Kunzmann, J. Siveke, H. Algül, E. Goekkurt +33 more
2020The Lancet Gastroenterology and Hepatology156 citations
Semantic Scholar
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
M. Moehler, A. Maderer, P. Thuss-Patience, B. Brenner +16 more
2020Annals of Oncology109 citations Open access
Semantic Scholar
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO.
R. Hofheinz, G. Haag, T. Ettrich, K. Borchert +16 more
202077 citations
Semantic Scholar
Pancreatic cancer-derived organoids – a disease modeling tool to predict drug response
P. Frappart, K. Walter, J. Gout, A. Beutel +19 more
2020United European Gastroenterology journal75 citations Open access
Semantic Scholar
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
A. Stein, D. Simnica, C. Schultheiss, R. Scholz +23 more
2021Journal for ImmunoTherapy of Cancer63 citations Open access
Semantic Scholar
Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial.
A. Stein, L. Paschold, J. Tintelnot, E. Goekkurt +22 more
2022JAMA Oncology60 citations Open access
Semantic Scholar
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
J. Valle, A. Vogel, C. Denlinger, A. He +21 more
2021The Lancet Oncology56 citations
Semantic Scholar
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer
A. Berger, D. Schwerdel, A. Reinacher-Schick, W. Uhl +16 more
2019Theranostics54 citations Open access
Semantic Scholar
Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
T. Seufferlein, T. Ettrich
2019Translational Gastroenterology and Hepatology49 citations Open access
Semantic Scholar
Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer
A. Berger, D. Schwerdel, T. Ettrich, Alexander Hann +4 more
2017OncoTarget48 citations Open access
Semantic Scholar
Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers
F. Finkelmeier, C. Czauderna, L. Perkhofer, T. Ettrich +5 more
2018Journal of Cancer Research and Clinical Oncology43 citations Open access
Semantic Scholar
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).
A. Stein, M. Binder, E. Goekkurt, S. Lorenzen +12 more
202039 citations
Semantic Scholar
1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
S. Al-Batran, G. Haag, T. Ettrich, K. Borchert +16 more
202030 citations Open access
Semantic Scholar
EVITA—a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity
R. Hofheinz, S. Lorenzen, J. Trojan, J. Ocvirk +12 more
2018Annals of Oncology30 citations Open access
Semantic Scholar
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.
J. Valle, Li-Yuan Bai, R. Orlova, E. Van Cutsem +15 more
202029 citations
Semantic Scholar
Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
V. Kunzmann, H. Algül, E. Goekkurt, G. Siegler +16 more
2019Annals of Oncology27 citations Open access
Semantic Scholar
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
J. Tintelnot, E. Goekkurt, M. Binder, P. Thuss-Patience +13 more
2020BMC Cancer26 citations Open access
Semantic Scholar
Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma.
K. Moek, W. Fiedler, J. V. von Einem, H. Verheul +11 more
2018Annals of Oncology23 citations Open access
Semantic Scholar
Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
J. Tintelnot, I. Ristow, M. Sauer, D. Simnica +23 more
2022Frontiers in Oncology22 citations Open access
Semantic Scholar
LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group
L. Perkhofer, J. Striefler, M. Sinn, B. Opitz +12 more
2021Annals of Oncology18 citations Open access
Semantic Scholar
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
S. Lorenzen, P. Thuss-Patience, C. Pauligk, E. Goekkurt +10 more
202018 citations
Semantic Scholar
Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).
A. Stein, M. Binder, S. Al-Batran, A. Hinke +11 more
201817 citations
Semantic Scholar
Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer
G. Manzini, T. Ettrich, M. Kremer, M. Kornmann +4 more
2018BMC Medical Research Methodology15 citations Open access
Semantic Scholar
Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315)
T. Ettrich, D. Modest, M. Sinn, J. Striefler +21 more
2024Journal of Clinical Oncology13 citations Open access
Semantic Scholar
Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).
M. Moehler, P. Thuss-Patience, B. Brenner, F. Longo +15 more
201713 citations
Semantic Scholar
203Pb-VMT-α-NET Scintigraphy of a Patient With Neuroendocrine Tumor
Dirk Müller, Hendrik Herrmann, M. Schultz, C. Solbach +2 more
2022Clinical Nuclear Medicine12 citations Open access
Semantic Scholar
LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study
T. Seufferlein, W. Uhl, H. Algül, H. Friess +16 more
2021Annals of Oncology11 citations Open access
Semantic Scholar
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial
G. Stocker, S. Lorenzen, T. Ettrich, Anna-Lina Herz +15 more
2023ESMO Open9 citations Open access
Semantic Scholar
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal
G. Sommerhäuser, A. Kurreck, S. Stintzing, V. Heinemann +17 more
2022BMC Cancer9 citations Open access
Semantic Scholar
Current status of immunotherapy in gastrointestinal malignancies
S. Lorenzen, F. Lordick, S. Loosen, F. Tacke +6 more
2020Zeitschrift für Gastroenterologie - German Journal of Gastroenterology9 citations
Semantic Scholar
NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis.
W. Uhl, T. Ettrich, A. Reinacher-Schick, H. Algül +14 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar
Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
M. Gaiser, S. Lorenzen, K. Merx, J. Trojan +13 more
2018Annals of Oncology9 citations Open access
Semantic Scholar
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial.
S. Buchholz, T. Ettrich, W. Uhl, M. Kornmann +14 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
LBA37 IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)
A. Vogel, A. Saborowski, J. Hinrichs, T. Ettrich +9 more
2021Annals of Oncology8 citations Open access
Semantic Scholar
Final results and OS of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer (mCRC).
M. Geissler, J. Riera-Knorrenschild, U. Martens, S. Held +10 more
2019Journal of Clinical Oncology7 citations
Semantic Scholar
Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score
M. Gaiser, S. Lorenzen, K. Merx, J. Trojan +13 more
2019Cancer Medicine7 citations Open access
Semantic Scholar
Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent – a multicenter survey in Germany and review of the literature
T. Ettrich, L. Schulte, N. Eitel, Kristin Ettrich +3 more
2017Zeitschrift für Gastroenterologie - German Journal of Gastroenterology6 citations
Semantic Scholar
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
J. Tintelnot, Alexander Stein, S. Al-Batran, T. Ettrich +16 more
2023Frontiers in Oncology5 citations Open access
Semantic Scholar
Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial
S. Göpel, W. Bethge, P. Martus, F. Kreth +9 more
2020Trials5 citations Open access
Semantic Scholar
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
N. Homann, S. Lorenzen, M. Schenk, P. Thuss-Patience +16 more
20205 citations
Semantic Scholar
Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial.
J. Tintelnot, A. Stein, L. Paschold, E. Goekkurt +15 more
2023Journal of Clinical Oncology4 citations
Semantic Scholar
Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial
S. Krug, T. Kegel, T. Gress, A. Rinke +9 more
2021BMC Cancer4 citations Open access
Semantic Scholar
ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers.
T. Goetze, Maria Gonzalez-Carmona, L. Kochen, N. Ağaoğlu +8 more
2024Future Oncology3 citations Open access
Semantic Scholar
1641P ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer
M. Ladekarl, S. Shim, T. Ettrich, A. Kestler +7 more
2023Annals of Oncology3 citations
Semantic Scholar
1495P FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Final results from the phase II RAMIRIS Study of the AIO
P. Thuss-Patience, S. Al-Batran, C. Pauligk, E. Goekkurt +10 more
20203 citations Open access
Semantic Scholar
MIRACLE: Green tea extract versus placebo for the prevention of colorectal adenomas: A randomized, controlled trial
T. Seufferlein, T. Ettrich, S. Menzler, H. Messmann +15 more
2019Annals of Oncology3 citations Open access
Semantic Scholar
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
S. Al-Batran, C. Pauligk, T. Goetze, J. Riera-Knorrenschild +9 more
2019Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Lorenzen×18
Invite
S. Lorenzen — researcher profile on SciRah
S. Al-Batran×16
Invite
S. Al-Batran — researcher profile on SciRah
T. Seufferlein×14
Invite
T. Seufferlein — researcher profile on SciRah
E. Goekkurt×14
Invite
E. Goekkurt — researcher profile on SciRah

A. Reinacher-Schick

×12

Invite

A. Reinacher-Schick — researcher profile on SciRah

L. Perkhofer×11

Invite

L. Perkhofer — researcher profile on SciRah

P. Thuss-Patience×10

Invite

P. Thuss-Patience — researcher profile on SciRah

Invite

A. Hinke — researcher profile on SciRah

J. Riera-Knorrenschild×8

Invite

J. Riera-Knorrenschild — researcher profile on SciRah

Invite

H. Algül — researcher profile on SciRah

Invite

N. Homann — researcher profile on SciRah

Invite

T. Goetze — researcher profile on SciRah